Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. März 2024 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
27. Februar 2024 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
22. Februar 2024 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
20. Februar 2024 08:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
09. November 2023 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative...
01. November 2023 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
10. Oktober 2023 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
05. September 2023 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
10. August 2023 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023...
08. August 2023 07:00 ET | Quelle: Monopar Therapeutics Inc.

Monopar Provides Encouraging Camsirubicin Clinical Data Update

WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...

Vorherige Seite

Nächste Seite